bicalutamide accord 150 mg apvalkotās tabletes
accord healthcare b.v., netherlands - bikalutamīds - apvalkotā tablete - 150 mg
lethyrin 25 mikrogrami/5 ml šķīdums iekšķīgai lietošanai
zentiva, k.s., czech republic - levotiroksīna nātrija sāls - Šķīdums iekšķīgai lietošanai - 25 µg/5 ml
lethyrin 50 mikrogrami/5 ml šķīdums iekšķīgai lietošanai
zentiva, k.s., czech republic - levotiroksīna nātrija sāls - Šķīdums iekšķīgai lietošanai - 50 µg/5 ml
lethyrin 100 mikrogrami/5 ml šķīdums iekšķīgai lietošanai
zentiva, k.s., czech republic - levotiroksīna nātrija sāls - Šķīdums iekšķīgai lietošanai - 100 µg/5 ml
abiraterone accord
accord healthcare s.l.u. - abiraterona acetāts - prostatas audzēji - endokrīnā terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.
abiraterone norameda 500 mg apvalkotās tabletes
norameda uab, lithuania - abirateroni acetas - apvalkotā tablete - 500 mg
abiraterone g.l. pharma 500 mg apvalkotās tabletes
g.l. pharma gmbh, austria - abirateroni acetas - apvalkotā tablete - 500 mg
abiraterone sandoz 500 mg apvalkotās tabletes
sandoz d.d., slovenia - abirateroni acetas - apvalkotā tablete - 500 mg
abiraterone sandoz 1000 mg apvalkotās tabletes
sandoz d.d., slovenia - abirateroni acetas - apvalkotā tablete - 1000 mg
abiraterone krka
krka, d.d., novo mesto - abiraterona acetāts - prostatas audzēji - endokrīnā terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.